Latest Regulatory Developments News

The Takeovers Panel has declined Atlas Arteria’s bid to block Diamond Infraco from dispatching its takeover Bidder’s Statement, prolonging uncertainty over the contested offer.

Bioxyne expands its LATAM footprint by securing the first international medicinal cannabis flower supply agreement in Costa Rica, with initial shipments valued over $500,000 planned before June 2026.

Pacific Edge is raising NZ$24 million to shore up its finances and support a crucial Medicare re-coverage bid following a steep revenue drop after losing Medicare reimbursement for its bladder cancer test. The company eyes a draft Medicare policy by September 2026 as a potential turning point.

Macquarie Bank Limited has posted a robust FY2026 result, with net profit attributable to ordinary equity holders soaring 74% to AUD 6.011 billion, underpinned by strong performances in its Banking and Financial Services and Commodities and Global Markets divisions.

PEXA Group delivered a 7.3% rise in Australian property transaction volumes in 3Q26 and saw steady UK remortgage growth despite macroeconomic uncertainty. The company reaffirmed its FY26 guidance, aiming for NPAT at the top of its $15m-$25m range.

Light & Wonder (ASX:LNW) posted modest revenue growth in 2025, driven by Gaming and iGaming segments, while SciPlay revenue dipped slightly. The company completed its Grover acquisition, settled a $128 million IP dispute with Aristocrat, and transitioned to a sole ASX listing.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

EMC Gold is pushing forward with a drilling campaign at its Salave Gold Project while navigating a procedural setback from the High Court of Asturias. The company also surrendered its Ivan Well tenement in WA and maintains a solid cash position of CAD$4.6 million.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

IDT Australia is poised for its strongest FY26 finish since its transformation began, forecasting a dramatic narrowing of EBITDA losses and revenue growth driven by strategic partnerships and operational upgrades.

The FDA has removed the postmarketing cardiac repolarization study requirement for Clinuvel's SCENESSE®, reflecting confidence in its long-term safety profile. This marks a regulatory milestone for the only approved treatment for erythropoietic protoporphyria in the US.

Yancoal Australia posted a record 38.6 million tonnes of attributable saleable coal in 2025, up 5% on 2024, but net profit after tax plunged 64% to A$440 million amid softer coal prices. The miner maintained disciplined cost control and declared A$769 million in fully franked dividends.